Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease.
The company plans to submit full results from the TEMPO-1 study for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson's disease.
Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.
The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy.
The trial met its primary endpoint, with a statistically significant reduction (improvement) from baseline compared to placebo in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale or MDS-UPDRS Parts II and III combined score at week 26.
The trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in both tavapadon dose groups compared to placebo at week 26.
The company noted that the safety profile observed in the TEMPO-1 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.